| Original language | English (US) |
|---|---|
| Pages (from-to) | 164-167 |
| Number of pages | 4 |
| Journal | European Journal of Heart Failure |
| Volume | 22 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2020 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction : results from the EVEREST trial. / Bhatt, Ankeet S.; Vaduganathan, Muthiah; Patel, Ravi B. et al.
In: European Journal of Heart Failure, Vol. 22, No. 1, 01.01.2020, p. 164-167.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction
T2 - results from the EVEREST trial
AU - Bhatt, Ankeet S.
AU - Vaduganathan, Muthiah
AU - Patel, Ravi B.
AU - Fonarow, Gregg C.
AU - Subacius, Haris P.
AU - Konstam, Marvin A.
AU - Zannad, Faiez
AU - Butler, Javed
AU - Greene, Stephen J.
N1 - Funding Information: Haris Subacius conducted all final analyses for this report with funding from the Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Conflict of interest: M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), and has served on advisory boards or received research funding from Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, and Boehringer Ingelheim. R.B.P. is supported by the NHLBI T32 postdoctoral training grant T32HL069771. G.C.F. reports research funding from the National Institutes of Health (NIH) and serving as a consultant for Amgen, Bayer, Medtronic, and Novartis. M.A.K. has received research support and consulting fees from LivaNova, Ironwood, and SC Pharma and consulting fees for data monitoring committee activity from Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Array, and Luitpold. F.Z. reports personal fees from Janssen, Bayer, Novartis, Boston Scientific, Resmed, Amgen, CVRx, Quantum Genomics, General Electric, Boehringer, AstraZeneca, Vifor Fresenius, Cardior, outside the submitted work. J.B. has received research support from the NIH, PCORI and the European Union; and serves as a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, SC Pharma, Vifor, and ZS Pharma. S.J.G. has received a Heart Failure Society of America/Emergency Medicine Foundation Acute Heart Failure Young Investigator Award funded by Novartis; has received research support from Amgen, Bristol-Myers Squibb and Novartis; has served on an advisory board for Amgen; and has served as a consultant for Amgen. All other authors declare no relevant disclosures. Funding Information: M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), and has served on advisory boards or received research funding from Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, and Boehringer Ingelheim. R.B.P. is supported by the NHLBI T32 postdoctoral training grant T32HL069771. G.C.F. reports research funding from the National Institutes of Health (NIH) and serving as a consultant for Amgen, Bayer, Medtronic, and Novartis. M.A.K. has received research support and consulting fees from LivaNova, Ironwood, and SC Pharma and consulting fees for data monitoring committee activity from Amgen, Boehringer‐Ingelheim, Bristol‐Myers Squibb, Array, and Luitpold. F.Z. reports personal fees from Janssen, Bayer, Novartis, Boston Scientific, Resmed, Amgen, CVRx, Quantum Genomics, General Electric, Boehringer, AstraZeneca, Vifor Fresenius, Cardior, outside the submitted work. J.B. has received research support from the NIH, PCORI and the European Union; and serves as a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, SC Pharma, Vifor, and ZS Pharma. S.J.G. has received a Heart Failure Society of America/Emergency Medicine Foundation Acute Heart Failure Young Investigator Award funded by Novartis; has received research support from Amgen, Bristol‐Myers Squibb and Novartis; has served on an advisory board for Amgen; and has served as a consultant for Amgen. All other authors declare no relevant disclosures. Conflict of interest:
PY - 2020/1/1
Y1 - 2020/1/1
UR - http://www.scopus.com/inward/record.url?scp=85076096188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076096188&partnerID=8YFLogxK
U2 - 10.1002/ejhf.1651
DO - 10.1002/ejhf.1651
M3 - Letter
C2 - 31797490
AN - SCOPUS:85076096188
SN - 1388-9842
VL - 22
SP - 164
EP - 167
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 1
ER -